Pach J, Gekeler F
Department für Augenheilkunde, Universitätsklinikum Tübingen, Schleichstrasse 12, Tübingen.
Klin Monbl Augenheilkd. 2013 May;230(5):512-8. doi: 10.1055/s-0032-1328471. Epub 2013 May 21.
Retinitis pigmentosa (RP) is a clinically and genetically heterogeneous group of hereditary retinal disorders, which lead to progressive loss of vision and finally blindness. Yet there is no approved therapy. Advances in unravelling underlying genetic disorders and pathophysiological mechanisms offer new therapeutic approaches of which some are summarised in this review.
We performed a systematic literature research for defined key words in PubMed.
New approaches to therapy for RP include: gene therapy, pharmacological treatment, neuroprotection, electrical stimulation, retinal prostheses, retinal transplantation and optogenetic therapy.
Recently there have been advances in new approaches for therapy of dystrophic retinal diseases. Advances in the different approaches are being made at different rates. Although there is no approved therapy yet, the future for treating RP at least in some patients looks promising.
视网膜色素变性(RP)是一组临床和遗传异质性的遗传性视网膜疾病,可导致视力逐渐丧失并最终失明。然而,目前尚无获批的治疗方法。在揭示潜在遗传疾病和病理生理机制方面取得的进展提供了新的治疗方法,本文综述了其中一些方法。
我们在PubMed中对特定关键词进行了系统的文献研究。
RP的新治疗方法包括:基因治疗、药物治疗、神经保护、电刺激、视网膜假体、视网膜移植和光遗传学治疗。
最近,营养不良性视网膜疾病的新治疗方法取得了进展。不同方法的进展速度不同。尽管目前尚无获批的治疗方法,但至少对部分患者而言,治疗RP的前景看起来很有希望。